Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.

Bristol Myers Squibb is facing down the expiration of patent protections for older drugs, but new drugs are starting to show promise.